Clinical Trials Browser

Phase 1/2 × INDUSTRY × exemestane × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT02732119 2021-05-05

TRINITI-1

Phase 1/2 Completed

104 enrolled 24 charts

Breast

Breast Neoplasms

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Phase 1/2 Terminated

14 enrolled 13 charts

Breast

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

Phase 1/2 Completed

127 enrolled 8 charts

Breast

Breast Neoplasms

NCT00417885 2010-09-21

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Phase 1/2 Terminated

6 enrolled 6 charts

Breast

Breast Neoplasms

Clinical Trials

PIKALO-1

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

MORPHEUS HR+BC

TRINITI-1

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

GLOW

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer